Literature DB >> 18092154

Electrophysiological profile of propiverine--relationship to cardiac risk.

Torsten Christ1, Erich Wettwer, Melinda Wuest, Manfred Braeter, Frank Donath, Pascal Champeroux, Serge Richard, Ursula Ravens.   

Abstract

Drugs that prolong the QT interval by blocking human ether-a-go-go (HERG) channels may enhance the risk of ventricular arrhythmia. The spasmolytic drug propiverine is widely used for the therapy of overactive bladder (OAB). Here, we have investigated the effects of propiverine on cardiac ion channels and action potentials as well as on contractile properties of cardiac tissue, in order to estimate its cardiac safety profile, because other drugs used in this indication had to be withdrawn due to safety reasons. Whole-cell patch clamp technique was used to record the following cardiac ion currents: rapidly and slowly activating delayed rectifier K+ current (I(Kr), I(Ks)), ultra rapidly activating delayed rectifier K+ current (I(Kur)), inwardly rectifying K+ current I(K1), transient outward K+ current (I(to)), and L-type Ca2+ current (I(Ca,L)). Action potentials in cardiac tissue biopsies were recorded with conventional microelectrodes. The torsade de pointes screening assay (TDPScreen) was used for drug scoring. Propiverine blocked in a concentration-dependent manner HERG channels expressed in HEK293 cells, as well as native I(Kr) current in ventricular myocytes of guinea pig (IC50 values: 10 microM and 1.8 microM respectively). At high concentrations (100 microM), propiverine suppressed I(Ks). I(K1) and the transient outward current I(to) and I(Kur) were not affected. In guinea-pig ventricular and human atrial myocytes, propiverine also blocked I(Ca,L) (IC50 values: 34.7 microM and 41.7 microM, respectively) and reduced force of contraction. Despite block of I(Kr), action potential duration was not prolonged in guinea-pig and human ventricular tissue, but decreased progressively until excitation failed altogether. Similar effects were observed in dog Purkinje fibers. Propiverine obtained a low score in the TDPScreen. In conclusion, in vitro and in vivo studies of propiverine do not provide evidence for an enhanced cardiovascular safety risk. We propose that lack of torsadogenic risk of propiverine is related to enhancement of repolarization reserve by block of I(Ca,L).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18092154     DOI: 10.1007/s00210-007-0231-1

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  41 in total

1.  Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study.

Authors:  W Dorschner; J U Stolzenburg; R Griebenow; M Halaska; G Schubert; G Mürtz; M Frank; F Wieners
Journal:  Eur Urol       Date:  2000-06       Impact factor: 20.096

Review 2.  Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.

Authors:  Luc M Hondeghem
Journal:  J Cardiovasc Electrophysiol       Date:  2006-03

Review 3.  Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS.

Authors:  D M Roden; R Lazzara; M Rosen; P J Schwartz; J Towbin; G M Vincent
Journal:  Circulation       Date:  1996-10-15       Impact factor: 29.690

4.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

5.  In-vitro binding of propiverine hydrochloride and some of its metabolites to serum albumin in man.

Authors:  P Meisel; S Langner; W Siegmund
Journal:  J Pharm Pharmacol       Date:  1997-03       Impact factor: 3.765

Review 6.  Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology.

Authors:  S G Priori; J Barhanin; R N Hauer; W Haverkamp; H J Jongsma; A G Kleber; W J McKenna; D M Roden; Y Rudy; K Schwartz; P J Schwartz; J A Towbin; A Wilde
Journal:  Eur Heart J       Date:  1999-02       Impact factor: 29.983

Review 7.  ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis.

Authors:  Icilio Cavero; William Crumb
Journal:  Expert Opin Drug Saf       Date:  2005-05       Impact factor: 4.250

8.  Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.

Authors:  S Rajamani; L L Eckhardt; C R Valdivia; C A Klemens; B M Gillman; C L Anderson; K M Holzem; B P Delisle; B D Anson; J C Makielski; C T January
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

Review 9.  Drug-induced torsade de pointes: from molecular biology to bedside.

Authors:  J Tamargo
Journal:  Jpn J Pharmacol       Date:  2000-05

10.  Mechanism of block and identification of the verapamil binding domain to HERG potassium channels.

Authors:  S Zhang; Z Zhou; Q Gong; J C Makielski; C T January
Journal:  Circ Res       Date:  1999-05-14       Impact factor: 17.367

View more
  4 in total

1.  The muscarinic receptor antagonist propiverine exhibits α(1)-adrenoceptor antagonism in human prostate and porcine trigonum.

Authors:  Melinda Wuest; Lambertus P Witte; Martina B Michel-Reher; Stefan Propping; Manfred Braeter; Gerhard J Strugala; Manfred P Wirth; Martin C Michel; Ursula Ravens
Journal:  World J Urol       Date:  2011-02-19       Impact factor: 4.226

Review 2.  Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.

Authors:  Karl-Erik Andersson; Lysanne Campeau; Brian Olshansky
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

Review 3.  Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.

Authors:  Kate McKeage
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859

4.  Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines.

Authors:  H R Lu; E Vlaminckx; A N Hermans; J Rohrbacher; K Van Ammel; R Towart; M Pugsley; D J Gallacher
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.